Plain-English translation of NCT04097067 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing whether a lower dose of radiation therapy (20 Gy) works as well as the standard higher dose (30 Gy) for treating early-stage follicular lymphoma or marginal zone lymphoma when it's located in the stomach or duodenum. Researchers will measure how well the treatment works 6 months after therapy ends and track how it affects quality of life and side effects.
Standard radiation therapy for these types of lymphoma uses a higher dose that can sometimes cause long-term side effects. This trial is trying to find out whether a lower dose can be just as effective, potentially reducing harm to healthy tissue while still curing the cancer.
You likely qualify if…
You likely don't qualify if…
You will receive daily radiation therapy sessions for 10 days (a total dose of 20 Gy delivered in small daily amounts). During treatment and at follow-up visits at 3 and 6 months after therapy ends, you'll have blood tests to measure how your body is responding and to check for any side effects. You'll also complete quality-of-life surveys to help researchers understand how the treatment affects your daily life.
AI-generated summary from trial data · Jun 24, 2026 · Not medical advice
Germany
Sponsor
University Hospital Muenster
Collaborators
International Lymphoma Radiation Oncology Group (ILROG)
Enrollment target
~83 participants
Started
September 2019
Primary completion
August 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in August 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Gabriele Reinartz, MD (Priv. Doz.)
Department of Radiation Oncology University Hospital Muenster
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.